David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.

David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.